WuXi PharmaTech officially launched the Hong Kong stock listing process, and the A-share “most cattle” is difficult to replicate.

Recently, WuXi PharmaTech submitted an IPO listing application to the Hong Kong Stock Exchange and officially launched its Hong Kong stock listing process. This is only a matter of more than three months after its A-share listing. If the Hong Kong stock market is finally completed, the medicine will be completed. Mingkang has become the third A+H listed pharmaceutical company after Shanghai Pharmaceutical and Fosun Pharma.

Some insiders said that the A+H share model of WuXi PharmaTech is very attractive to many mainland enterprises. First of all, from the perspective of financing, the scale of financing for listing in the two places will be greater; secondly, from the perspective of equity structure, The new rules of the Hong Kong Stock Exchange accept the "different rights of the same shares" structure. In the process of the development of new economic companies, the controlling shareholder can achieve the purpose of controlling the company by virtue of "the same rights and different rights"; finally, from the perspective of globalization, listed in Hong Kong It will enhance the company's international reputation. For companies with international strategies or overseas M&A plans, the issuance of H shares is undoubtedly the first step in the implementation strategy.

According to the announcement, the number of H shares issued by WuXi PharmaTech accounted for 10% to 15% of the total share capital of the company after the issue (before the execution of the over-allotment option), and the underwriters (bookkeepers) were granted no more than the H shares issued as mentioned above. 15% of the over-allotment rights. The use of funds will be used to expand the scale of operations in China, the United States and Hong Kong, acquire CRO and CMO/CDMO companies, invest in companies that have innovative business models and growth potential in the medical industry , develop high-end technology, and repay banks. Loans and supplementary liquidity, etc.

For the issue of H shares, WuXi PharmaTech has previously stated that having a “A+H” dual financing platform will enable investors at home and abroad as well as customers at home and abroad to understand the company more intuitively and quickly, effectively establishing the company's image in the global capital market, and quickly Enhance the company's international reputation; at the same time, the "A+H" dual financing platform will provide strong capital support for the company's rapid and healthy development in the future, which will enable the company's global business to develop faster and better.

In August of this year, WuXi PharmaTech handed over the first semi-annual report since the A-share listing. The annual report shows that in the first half of 2018, WuXi PharmaTech achieved operating income of 4.409 billion yuan, an increase of 20.29% year-on-year; The net profit of the company's shareholders was 1.271 billion yuan, a year-on-year increase of 71.31%; the net profit after deduction was 827 million yuan, a year-on-year increase of 32.30%, achieving double growth in operating income and net profit.

From the perspective of the business sector, WuXi PharmaTech's laboratory services in China achieved revenue of 2.416 billion yuan, up 21.65% year-on-year; laboratory services in the United States achieved revenue of 546 million yuan, down 1.93% year-on-year; Clinical research and other CRO services realized revenue of 231 million yuan, a year-on-year increase of 58.80%; CMO/CDMO business realized income of 1.209 billion yuan, a year-on-year increase of 26.80%.

WuXi PharmaTech said that the growth in the first half of the year was mainly due to the growth of the company's laboratory services and clinical CRO business in China. Since 2018, WuXi PharmaTech has provided a category for more than 30 domestic pharmaceutical companies and start-ups. Innovative drug research and development services, completed the clinical trial application of 8 research new drug (IND) projects for customers, and obtained clinical trial approvals (CTA) for 8 projects, accounting for about 16% of the same period of domestic similar drugs.

Some analysts pointed out that from the first financial report after the listing of WuXi PharmaTech A shares, the raised funds and brand effect brought by the company's successful issuance of A shares this year also played a supporting role in maintaining stable growth of the company's performance. Although optimistic all the way (has created a record of 16 consecutive daily limit in A shares), the gross profit margin of the US laboratory services disclosed in the semi-annual report is only 22.93%, a decrease of 29.49% year-on-year. On the trading platform, Hong Kong stock investors are obviously more concerned about the overseas development of the company, and the data disclosed by it shows that the growth rate of its domestic business is obviously far higher than that of the overseas market. In this way, the "most bullish new shares" in the A-share market is in full swing. Hong Kong stocks may not be able to stage again.

Dehydrated Potato

Dehydrated potato is an indispensable vegetable in daily life and diet. Potatoes have high nutritional value and low price, and are the favorite food of the masses. Dehydrated potatoes should be selected with large tubers, smooth surface, thin skin, shallow and few bud eyes, white or light yellow flesh, dry matter not less than 21%, and starch content not more than 18%. Rose, Castle Peak, Triumph and other varieties are appropriate.

Dehydrated Potato,Dehydrated Potato Nutrition,Dehydrated Potato Chips,Dehydrated Potato Dices

Laian Xinshuyu Food Co., Ltd , https://www.xinshuyufood.com